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Introduction
Gastro-oesophageal reﬂux disease (GORD) is a com-
mon disorder, with 10–20% of the population esti-
mated to have the condition and consultations for
dyspepsia accounting for 1.2–4% of all primary care
consultations in the UK (1). The cardinal symptoms
of GORD, heartburn and acid regurgitation, are
often accompanied by other symptoms, which
together have a substantial negative impact on
patients’ quality of life (2,3). Despite the efﬁcacy of
proton pump inhibitor (PPI) therapy, a number of
studies have indicated that a signiﬁcant minority
of GORD patients (20–25%) (4) receiving PPIs con-
tinue to have unresolved symptoms, accompanied by
continuing impairment of their quality of life (5,6).
The National Institute for Health and Clinical
Excellence recommends that general practitioners
(GPs) adopt a symptom-driven approach to patient
management (7), which is in keeping with the obser-
vation that symptoms, rather than endoscopic
appearances, are a better guide for assessing the
response to therapy. Jones et al. (8) have recently
shown that patients who respond best to therapy
subsequently enjoy the best quality of life.
Primary care physicians continue to experience
problems in managing GORD, and there is evidence
that patients and clinicians perceive the severity and
impact of symptoms differently (9). To improve the
ascertainment of patients’ symptoms, a number of
patient questionnaires have been developed, most
recently the GIS (GORD Impact Scale), which has
been extensively validated in the primary care setting
and shown to be responsive to changes in patients’
symptoms (10).
In the face of persistent GORD symptoms, when
attention has been paid to lifestyle factors and an
explanation about mechanisms and the effects of
therapy has been provided, clinicians are faced with
the dilemma of the appropriate next therapeutic step,
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SUMMARY
Background: Some patients with gastro-oesophageal reﬂux disease (GORD)
remain symptomatic despite proton pump inhibitor (PPI) treatment. There is a need
to determine the most appropriate management of these patients. Aims: To
assess the effectiveness of esomeprazole 40 mg in GORD symptoms persisting in
patients receiving a full daily dose PPI. Methods: In this multi-centre open label
study patients who had received full daily dose PPI for 8 weeks, but were still
experiencing persistent GORD symptoms, were treated with esomeprazole 40 mg
for 8 weeks (n = 99). The primary outcome variable was the change in the
frequency of heartburn. Patient-reported outcomes were also assessed using
the Reﬂux Disease Questionnaire (RDQ) and the GORD Impact Scale (GIS).
Results: The mean frequency of heartburn was reduced by 78% from 4.4 days a
week to 1 day a week at the end of the 8-week treatment period (p < 0.0001).
Other GORD symptoms were also signiﬁcantly reduced following of treatment with
esomeprazole (all p < 0.0001). All RDQ dimensions and the level of symptom con-
trol as measured by the GIS also showed signiﬁcant improvement at 8 weeks.
Conclusions: In patients with persistent GORD symptoms despite full dose daily
PPI therapy, esomeprazole 40 mg signiﬁcantly improved the frequency and severity
of all GORD symptoms.
What’s known
A signiﬁcant minority of patients treated for gastro-
oesophageal reﬂux disease (GORD) remain
symptomatic despite therapy with proton pump
inhibitor agents. The reasons for this are not clear,
nor are the best approach to management. More
effective acid suppression is one possible
management strategy.
What’s new
Treatment with esomeprazole 40 mg daily in
patients with GORD who have responded
incompletely to a full daily dose of other PPIs is
associated with a signiﬁcant reduction in symptoms
as measured with the Reﬂux Disease Questionnaire
and an improvement in quality of life, measured
with Gastro-oesophageal Disease Impact Scale.
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arrange an endoscopy or to change the medication.
Esomeprazole has been shown to provide better acid-
control than other PPIs (11–13), and is also more
effective at healing oesophagitis (14–16). This study
was undertaken to assess whether esomeprazole
40 mg is effective when other PPIs, prescribed at a
full daily dose for a period of up to 8 weeks,
have failed to adequately control the symptoms of
GORD.
Methods
Study design
We undertook a multi-centre open label study in the
UK, in which patients were treated with esomepraz-
ole 40 mg for 8 weeks. Patients attended a screening
visit before initiation of study treatment (baseline)
followed by two additional clinic visits at 4 and
8 weeks.
Patients
Patients who were followed up by their GP for
GORD treatment were invited to participate in the
study when it had become apparent that they were
still experiencing symptoms of GORD, deﬁned as
heartburn, epigastric pain or acid regurgitation,
despite being on their current PPI therapy. This is to
reﬂect how patients are currently managed in pri-
mary care. Informed consent was obtained at the
screening visit and patients eligible to enter the study
were issued with study medication. Patients’ symp-
tom status was reassessed after 4 weeks of treatment
and at the third visit at 8 weeks. Patients eligible for
inclusion in the study were men and women aged
over 18 who were currently being treated for GORD
with a PPI at full daily dose (i.e. omeprazole 20 mg
daily, lansoprazole 30 mg daily, rabeprazole 40 mg
daily) for a preceding period of up to 8 weeks. In
order to be eligible, patients were required to report
persisting GORD symptoms of heartburn, acid regur-
gitation or epigastric pain during the 7 days prior to
the ﬁrst visit, either as 4 days with mild symptoms
or 2 days with moderate to severe symptoms (see
Table 1).
Patients were excluded from the trial if they had
had more than one previous course of full dose PPI
in the last year or had been treated for more than
8 weeks with their current full dose PPI. Patients
who had previously taken esomeprazole or those
who were using an H2 receptor antagonist were also
excluded. Patients with serious gastrointestinal, car-
diovascular, metabolic or other conditions were
excluded, as were those with a history of upper gas-
trointestinal surgery. Patients with irritable bowel
syndrome, with any evidence of gastrointestinal
alarm symptoms or severe concurrent disease or
mental illness, were also excluded. Continuous con-
current therapy with a range of potentially interactive
drugs was also an exclusion criterion, as were preg-
nancy and lactation, chronic alcoholism, current
malignancy, known hypersensitivity to esomeprazole
or participation in a clinical study during the last
90 days.
Efﬁcacy assessment
The primary outcome of the study was an assessment
of the change in the frequency of heartburn from
baseline to the end of the study at 8 weeks .The sec-
ondary outcome measures included assessments of
the change of frequency of heartburn after 4 weeks
of treatment, and the change in severity and fre-
quency of heartburn, epigastric pain and acid regur-
gitation at 4 and 8 weeks.
At each visit, patients were questioned in a stan-
dardised manner by the investigator about the fre-
quency of their GORD symptoms. The overall
severity of each symptom was measured on a 4-point
scale from zero (none) to three (severe) (see Table 1).
Patients were also asked how much relief they
obtained from their over-the-counter (OTC) medica-
tion, during the previous 12 months.
Other patient-reported outcome measures were
changes in symptom control from baseline to
8 weeks as assessed by the RDQ (Reﬂux Disease
Questionnaire) and the GIS. The RDQ is a 12-item
self-administered questionnaire design to assess the
frequency and severity of heartburn, acid regurgita-
tion and epigastric pain (17). Symptom frequency
and severity are scored on a 6-point Likert scale.
Twelve items are combined into three dimensions:
heartburn, regurgitation, dyspepsia. The mean of all
three dimensions gives a total score. The speciﬁc
GORD dimension is determined by the mean of the
dimensions of heartburn and regurgitation. Physi-
cians’ assessments of GORD symptoms were corre-
lated with the RDQ scores.
The GIS is a reliable tool, validated for use in clin-
ical practice (10). It consists of nine questions, which
ask about the frequency of a range of symptoms,
Table 1 Symptom severity rating
Mild (1) Awareness of symptom(s) which is⁄are
easily tolerated
Moderate (2) Discomfort sufﬁcient to cause interference
with normal activities
Severe (3) Incapacitating with inability to perform
normal activities
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the cardinal symptoms of reﬂux disease, each scored
on a 4-point scale from ‘never’ to ‘daily’. The level
of symptom control for individual patients is deter-
mined by the number of ticks in each of the four
parameters (never-daily). Nine ticks in the ‘never’
box signiﬁes that GORD symptoms are well-con-
trolled; six ticks in the ‘never’ box indicates ‘fairly
well-controlled’ GORD symptoms; > 3 ticks outside
the ‘never’ box signiﬁes uncontrolled GORD; > 5
ticks outside the ‘never’ box signiﬁes poorly con-
trolled; and all nine ticks outside the ‘never’ box sig-
niﬁes ‘very poorly controlled’. This outcome variable
reﬂects how physicians currently use the GIS in
determining how well-controlled the GORD symp-
toms are in a patient.
Tolerability and safety assessment
The nature, incidence and severity of serious adverse
events (SAEs) and adverse events leading to discon-
tinuation of a patient from study treatment were
analysed for all patients who took at least one dose
of the investigational product and for whom post-
dose information was available.
Statistical analysis
The primary and secondary efﬁcacy and patient-
reported outcome variables were analysed using a full
analysis set, which included all patients with at least
one assessment of efﬁcacy after initiation of study
treatment. The safety variables were analysed using
the safety analysis set, which consisted of all patients
who took at least one dose of the investigational
product, and for whom postdose information was
available. For the primary and secondary efﬁcacy
variables, the changes from baseline to 4 and 8 weeks
scores in the frequency and severity of the GORD
symptoms of heartburn, acid regurgitation and epi-
gastric pain were analysed by the Wilcoxon signed
rank test.
Secondary patient-reported outcome variables,
including the changes from baseline to week 4 and
week 8 scores on the RDQ global and dimension
scores were analysed by the Wilcoxon signed rank
test. The GIS data were summarised using descriptive
statistics. The correlation between the RDQ domain
scores and the physicians’ assessment of these symp-
toms were analysed using the Spearman rank correla-
tion coefﬁcient. Statistical analyses were performed
by using the sas system (SAS version 8.2, SAS Insti-
tute Inc., Cary, NC).
Sample size
The sample size calculation was based on an estima-
tion of the change in frequency of heartburn from
baseline to 8 weeks. To detect a reduction (treatment
effect) of at least 1 day in the frequency of heartburn
during the previous week, assuming a standard devi-
ation of 2.8 and at the 5% signiﬁcance level with
90% power, 85 patients were required in the study.
We assumed a dropout rate of 15% and therefore
planned to enrol approximately 100 patients.
Results
In total, 99 patients from 17 research sites in the UK
were enrolled in the study. All patients entering the
study were analysed for safety and 94 (95%) were
analysed for efﬁcacy and patient-reported outcomes
(ﬁve patients were excluded from the full analysis set
because no assessment of efﬁcacy was made after
baseline data were collected).
The demographic features and current treatment
of these patients are shown in Table 2. The mean age
of the population was 46 years and all were of
Caucasian origin. Reﬂux symptoms had been present
for a mean of 4.5 years and heartburn had been
experienced for a mean of 4.4 days during the week
before the trial. 63% of the patients had little or no
relief of symptoms when using OTC preparations in
the last 12 months in addition to taking their current
PPI.
Changes in the primary and secondary outcome
variables are summarised in Figures 1 and 2.
Table 2 Baseline characteristics and treatment of
patients included in the efﬁcacy analysis
Demographic characteristic n =9 4
Gender (n and % of patients)
Male 37 (39.4%)
Female 57 (60.6%)
Age (years)
Mean (SD) 46.1 (16.1)
Race (n and % of patients)
Caucasian 94 (100.0%)
History of GORD symptoms (months)
Mean (SD) 56.1 (97.9)
Duration of current episode of GORD (weeks)
Mean (SD) 9.53 (8.78)
Frequency of heartburn in last week (days)
Mean (SD) 4.4 (2.3)
Previous PPI (n and % of patients)
Lansoprazole 30 mg 25 (26.6%)
Omeprazole 20 mg 67 (71.3%)
Rabeprazole 40 mg 2 (2.1%)
GORD, gastro-oesophageal reﬂux disease; PPI, proton pump
inhibitor.
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from 4.4 days a week to 1 day a week at the end of
the 8-week treatment period with esomeprazole
40 mg p < 0.0001 (95% CI: –4.0, )2.8). This corres-
ponds to a mean reduction of 78% in the frequency
of heartburn.
Control of heartburn symptoms was achieved
within 4 weeks of starting treatment with esomepraz-
ole with a mean reduction in the frequency of heart-
burn to 1 day a week (mean change in frequency of
heartburn from baseline )3.4 days, p < 0.0001) Fre-
quency of acid regurgitation was signiﬁcantly reduced
by 2.6 days per week at 8 weeks (95% CI: )3.1, )2.1;
p < 0.0001) as was the frequency of epigastric pain
by 3.6 days per week after 8 weeks of treatment with
esomeprazole (95% CI: )4.2, )3.0; p < 0.0001) . The
beneﬁt became apparent as early as 4 weeks after
initiation of treatment with esomeprazole 40 mg.
This was also accompanied by a signiﬁcant reduction
in the severity of heartburn from baseline to 8 weeks
(Figure 2) as well as the severity of acid regurgitation
and epigastric pain with esomeprazole (all p <
0.0001). At all time points, there was a substantial
and statistically signiﬁcant reduction in GORD symp-
tom frequency and severity.
These changes are reﬂected in improvements in
the RDQ global score and in the heartburn, acid
regurgitation, dyspepsia and GORD dimension scores
of the RDQ at 8 weeks of esomeprazole 40 mg treat-
ment (Figure 3). Similar results were observed after
4 weeks of treatment.
The RDQ scores and physicians’ assessment were
also well correlated. Changes in the RDQ scores
(heartburn, acid regurgitation, epigastric pain) and
changes in physician’s assessment of these symptoms
were well correlated (Spearman’s rank correlation
coefﬁcient 0.80, 0.83 and 0.69 respectively).
The GIS scores also showed a considerable
improvement at 4 and 8 weeks and the level of
symptom control, assessed by summarising the scores
on the GIS, is shown in (Figure 4) emphasising that
patients gradually moved from poorly controlled to
well-controlled over the 8 week study period.
Safety
The mean duration of exposure to esomeprazole
40 mg was 51 days and, overall, the drug was well-tol-
erated. There were three SAEs: admission for myocar-
dial infarction, chronic obstructive pulmonary disease
(COPD) exacerbation and balance disorder. None of
the SAEs were considered causally related to the study
drug. Four of the adverse events led to discontinua-
tion – diarrhoea, abdominal distension, ﬂatulence,
exacerbation of GORD – and were assessed as related
to esomeprazole treatment. Diarrhoea was the only
adverse event reported by more than one patient.
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Figure 1 Change in frequency of symptoms (*p < 0.0001; n = 94)
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Figure 2 Change in the grade of heartburn severity (n = 94)
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This study shows that patients who continue to
experience GORD symptoms on full dose PPI ther-
apy obtain substantially improved symptom control
when treated with esomeprazole 40 mg daily. We
have shown improvements, which are statistically sig-
niﬁcant and considered to be clinically important, in
a range of patient-reported outcome measures,
including the RDQ and the GIS.
The persistence of reﬂux symptoms in patients
taking PPIs is now a well-recognised problem.
Although we do not have a measure of compliance
in our patients, non-response has been observed in
fully compliant subjects. This has a number of impli-
cations for clinicians. The ﬁrst of these, of course, is
to ensure that patients are assessed adequately and
the introduction of the GIS, designed to support
clinicians’ questioning patients about their symptom
status, is one potentially valuable approach to ensu-
ing that this takes place. When appropriately ques-
tioned, as many as 25% of patients on PPIs report
persistent symptoms (4), and these are associated
with substantial impairment of quality of life (2,3).
Confronted with a ‘non-responder’ to full-dose PPI
therapy, the primary care clinician has a number of
options, which include specialist referral and investi-
gation with upper gastrointestinal endoscopy and
possibly pH monitoring and manometry. Another
option is to prescribe a double dose of the current
PPI, in order to achieve better acid suppression and
consequent symptomatic improvement. However,
there are data to suggest that this may not be a clini-
cally effective approach. Rohss et al. (11) showed
that esomeprazole maintains intragastric pH above 4
for a longer period of time than omeprazole 40 mg,
equating to an additional 1.5–2 h of acid suppres-
sion. There is also evidence from the same study that
interpatient variability in the percentage of the time
for which gastric pH exceeds 4 is signiﬁcantly less
with esomeprazole 40 mg than with omeprazole
40 mg daily. The study by Wilder-Smith et al. (12)
compared esomeprazole 40 mg daily with lansopraz-
ole 60 mg daily (i.e. double the normal daily dose)
and found that acid control, in terms of the duration
of time during which intragastric pH exceeded 4,
was signiﬁcantly better with esomeprazole than with
high-dose lansoprazole. Finally, a recent meta-analy-
sis (18), conducted as part of a Cochrane system-
atic review, and which examined 18 randomised
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dose PPI, was unable to identify data to support the
practice of doubling the dose of PPI therapy in
patients who do not respond to standard dose ther-
apy, with the possible exception of esomeprazole
40 mg once daily.
These choices have signiﬁcant resource implica-
tions for health services, both in terms of the costs
of investigations, repeated visits to the GP and the
costs of drugs. In some healthcare systems, a double
dose of a standard PPI may be more expensive than
a standard dose of esomeprazole. The availability of
more effective acid suppression, through the use of
esomeprazole 40 mg daily, offers a more rational and
potentially more cost-effective approach as it rapidly
controls GORD patients’ symptoms thereby reducing
the need for repeat GP visits and referral for endos-
copy.
The strengths of this study include its pragmatic
approach, in which events in real clinical practice
were captured and clinicians were asked to initiate
esomeprazole 40 mg daily in patients whose GORD
symptoms were not adequately controlled on their
current PPI. These patients were being cared for in
primary care, by GPs, and the study replicates a
plausible sequence of events that does not involve
specialist referral or investigation.
A signiﬁcant weakness of the study, of course, is
that we did not adopt a randomised design, by allo-
cating patients to either esomeprazole or to a com-
parator drug (or to placebo). We considered that an
open-label approach was a more appropriate design
for this study, in which a placebo comparison would
have been inappropriate (because of persisting symp-
toms), and continuation with a less effective agent
also raises design and ethical questions. In this study,
the patients acted as their own controls although, of
course, we cannot exclude the additional beneﬁt
experienced by patients simply by virtue of being
part of a clinical trial. The use of epigastric pain as
an inclusion criterion and the exclusion of patients
with irritable bowel syndrome may limit the genera-
lisability of our ﬁndings, but we set out to study a
patient population likely to be representative of
patients with predominant GORD in primary care.
Overall, the results of the study indicated that
patients whose GORD symptoms remain uncon-
trolled despite receiving a full dose of a PPI beneﬁt
from a change to esomeprazole 40 mg, with signiﬁ-
cant reduction in the frequency and severity of
the three predominant GORD symptoms within
4–8 weeks. We think that this approach should be
adopted before clinicians consider specialist interven-
tion or endoscopic investigation, in patients without
alarm symptoms or other concerns. This study’s
ﬁndings also demonstrated the value of using
patient-reported questionnaires as a tool in disease
management. The RDQ and the GIS were easy to
use, responsive and performed well in this study and
the GIS, in particular, has a potentially valuable part
to play in routine management of patients with
GORD.
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